Accelerating Practical Application and Commercialization through a Capital and Business Alliance with M3
First written in FY2016-Q4. 6 of 7 entries say "Restated". Latest entry: FY2021.
No other company in this theme has enough history to compare yet.
- FY2021RestatedAnnual report
「At a meeting of the Board of Directors held on 11 November 2020, the company resolved to absorb its wholly owned subsidiary ＨＭＴバイオメディカル株式会社 and entered into a merger agreement on the same date.」
The capital and business alliance agreement with M3 and the collaborative framework centered on the practical application of depression biomarkers remain in place according to the list of agreements. - FY2020RestatedAnnual report
「Subscription for the third-party allotment of shares conducted by the company, as well as business cooperation and the establishment of a collaborative framework centered on the practical application of depression biomarkers.」
Continuing the subscription for the third-party allotment of shares through the capital and business alliance with M3, and the collaborative framework aimed at the practical application of depression biomarkers. - FY2019RestatedAnnual report
「Subscription for the third-party allotment of shares conducted by the company, as well as business cooperation and the establishment of a collaborative framework centered on the practical application of depression biomarkers.」
Continuing to support the practical application of depression biomarkers through the capital and business alliance with M3. - FY2017RestatedAnnual report
「In June 2016, we entered into a capital and business alliance agreement with M3,Inc. and conducted a third-party allotment of shares to M3,Inc., 株式会社平田牧場, 株式会社山形銀行 and 株式会社荘内銀行. We subsequently undertook activities to expand the metabolome analysis business and accelerate the practical application and commercialization of depression biomarkers.」
Reiterates the capital and business alliance with M3 and the third-party allotment of shares, together with the resulting business expansion and acceleration of practical application. - FY2017-Q2RestatedAnnual report
「In June 2016, we entered into a capital and business alliance agreement with M3,Inc. (hereinafter, “M3”) and conducted a third-party allotment of shares to M3,Inc., 株式会社平田牧場, 株式会社山形銀行 and 株式会社荘内銀行. We subsequently undertook activities to expand the metabolome analysis business and accelerate the practical application and commercialization of depression biomarkers.」
Reiterates the capital and business alliance with M3 and the third-party allotment of shares, together with the resulting business expansion and acceleration of practical application. - FY2017-Q1RestatedAnnual report
「In June 2016, we entered into a capital and business alliance agreement with M3,Inc. (hereinafter, “M3”) and conducted a third-party allotment of shares to M3,Inc., 株式会社平田牧場, 株式会社山形銀行 and 株式会社荘内銀行. We subsequently undertook activities to expand the metabolome analysis business and accelerate the practical application and commercialization of depression biomarkers.」
Reiterates the capital and business alliance with M3, the third-party allotment of shares, and the resulting business expansion and acceleration of practical application. - FY2016-Q4First statedAnnual report
「We entered into a capital and business alliance agreement with M3,Inc. (hereinafter, “M3”) to accelerate the practical application and commercialization of depression biomarkers, and conducted a third-party allotment of shares to M3,Inc., 株式会社平田牧場, 株式会社山形銀行 and 株式会社荘内銀行.」
The company states that it will accelerate the practical application and commercialization of depression biomarkers through its alliance with M3. The agreement commenced on 24 May 2016 and has no fixed term.